Drug Profile
Research programme: cannabidiol therapeutics - ANANDA Scientific./Yissum/Hadasit/Kennedy Trust for Rheumatology Research
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Hadassah Medical Organization; Hebrew University of Jerusalem; The Kennedy Trust for Rheumatology Research
- Developer ANANDA Scientific; Hadasit; The Kennedy Trust for Rheumatology Research; Yissum Research Development Company
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action Cannabinoid receptor CB1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus; Inflammation; Ischaemic heart disorders; Vascular disorders
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for research development in Diabetes-mellitus in Israel
- 28 Apr 2019 No recent reports of development identified for research development in Diabetes-mellitus in United Kingdom
- 28 Apr 2019 No recent reports of development identified for research development in Diabetes-mellitus in USA